HD-OPM Archive
Topics › Statins

STAREE: atorvastatin cut major CV events 30% in adults 70+, not disability-free survival

Louis Nervegna · Aug 29, 2026 · ♥ 4 reactions · 0 comments · original Facebook post
StatinsAging & longevityHeart attack, stroke & procedures
AI summary & key facts

A shared summary of the STAREE trial presented at ESC 2026: 9,971 adults 70+ without CVD, diabetes or dementia received atorvastatin 40 mg or placebo for a median 5.9 years. Major cardiovascular events fell 30% (6.0% vs 8.3%) but disability-free survival did not improve significantly.

#stareeHD #statinsHD #statinselderlyHD #statinsdementiaHD #atorvastatinHD #elderlyHD

Research cited

Shared from MRCP UK · original post

STAREE Trial — Statins for Primary Prevention in Older Adults

The STAREE trial, presented at ESC Congress 2026, provides important randomized evidence supporting statin therapy for the primary prevention of cardiovascular disease in healthy older adults.

Study Population

9,971 adults aged ≥70 years who were living independently and had:

No established cardiovascular disease
No diabetes mellitus
No dementia

Mean age was 74.7 years, and 52% were women.

Intervention

Atorvastatin 40 mg once daily vs. Placebo
Median follow-up: 5.9 years

Major Cardiovascular Events

Atorvastatin produced a significant 30% relative reduction in major cardiovascular events:

6.0% vs 8.3%
HR 0.70; 95% CI 0.61–0.82; P<0.001

The cardiovascular endpoint included:

Cardiovascular death
Nonfatal myocardial infarction
Stroke
Coronary revascularization

Disability-Free Survival

Atorvastatin did not significantly improve disability-free survival, defined by survival free from dementia and persistent physical disability.

12.8% vs 13.6%
HR 0.94; 95% CI 0.84–1.05; P=0.25

Safety

Serious adverse events were uncommon and occurred at the same rate in both groups (2.7%), although musculoskeletal, hepatobiliary, and diabetes-related adverse events were more frequent with atorvastatin.

In selected adults ≥70 years without established cardiovascular disease, atorvastatin significantly reduced major cardiovascular events, although it did not prolong disability-free survival.

Statin initiation in older adults should still be individualized according to overall cardiovascular risk, frailty, comorbidities, life expectancy, potential adverse effects, and patient preferences.

STAREE results were presented today at ESC Congress 2026 and simultaneously published in the New England Journal of Medicine.

May be an image of text that says 'MONASH University MONASH PUBLIC HEALTH REVENTIVE MEDICINE STATINS IN REDUCING EVENTS IN THE ELDERLY (STAREE) Effects of Atorvastatin on Cardiovascular Events and Disability Free Survival in Older People Professor Sophia Zoungas MBBS PhD on behalf of The STAREE Investigators SCHOOL OF PUBLIC HEAL TH AND PREVENTIVE MEDICINE MONASH UNIVERSITY MELBOURNE AUSTRALIA European Society uguesesreouaue of Cardiology Congress 2026 Munich Germany'May be an image of textMay be an image of slow loris and text that says 'CONCLUSIONS MONASH PUBLIC HEALTH AND PREVENTIVE MEDICINE STAREE is the first arge scale trial of atorvastatin for primary prevention to show cardiovascular benefit in people aged 70 years and older. Whilst no benefit on disability-free survival was demonstrated, this remains an important outcome for older people and the focus of further research. Our data underscore the safety of use of statins in older people. MONASH University MONASH PUBLICHEALTH PUBLIC HEALTH AND ANDPREVEN PREVENTIVE MEDICINE StaREE สิรรันดอ ร้นบดัษ nteEitrty w.iohmihoe.ficorty ආරෙක'
← newer: Overview of the seven commonly used statins and how statins older: STAREE: statins reduced events 30% in healthy adults 70+, NN →